Why an active comparator changes what a trial can say

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The phase 2 type 2 diabetes trial included dulaglutide, an approved long-acting GLP-1 receptor agonist, as an active comparator alongside placebo. That allowed retatrutide's glycaemic and weight effects to be set against an existing therapy under identical conditions. The higher retatrutide groups exceeded the comparator on both measures.

What an active comparator adds

Placebo tells you whether a compound does anything. An active comparator tells you how it performs against what already exists, in the same participants, over the same period, assessed the same way. That is a different and more demanding question.

The comparator dose used was a standard clinical dose of the approved drug, which anchors the comparison to real practice.

What was found

At 24 and 36 weeks, reductions in glycated haemoglobin in the higher retatrutide groups were greater than with dulaglutide, and weight reduction was greater across the retatrutide groups. The lowest retatrutide group was comparable to the comparator on glycaemia.

Adverse event profiles were qualitatively similar — predominantly gastrointestinal — with frequency tracking retatrutide dose.

The limits of one comparison

One comparator, one dose of it, one trial of 281 people over 36 weeks. That is evidence about retatrutide relative to dulaglutide under those conditions; it is not evidence about retatrutide relative to GLP-1 receptor agonists as a class, nor relative to the dual agonist, which was not an arm.

Pages that extrapolate from this trial to a general ranking of the class have gone further than the data.

Supply

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What an active comparator adds?

Placebo tells you whether a compound does anything. An active comparator tells you how it performs against what already exists, in the same participants, over the same period, assessed the same way. That is a different and more demanding question.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.